AMSTERDAM & BOSTON & SEATTLE--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and ...
~ Agreement grants VectorY the exclusive right to evaluate and license Shape’s non-invasive, deep-brain penetrating AAV5-derived capsid for vectorized antibodies against three targets ~ ~ License will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback